MA50041A - Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci - Google Patents
Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ciInfo
- Publication number
- MA50041A MA50041A MA050041A MA50041A MA50041A MA 50041 A MA50041 A MA 50041A MA 050041 A MA050041 A MA 050041A MA 50041 A MA50041 A MA 50041A MA 50041 A MA50041 A MA 50041A
- Authority
- MA
- Morocco
- Prior art keywords
- preparation
- methods
- same
- spirocyclic compounds
- spirocyclic
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762551721P | 2017-08-29 | 2017-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50041A true MA50041A (fr) | 2020-07-08 |
Family
ID=65527860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050041A MA50041A (fr) | 2017-08-29 | 2018-08-28 | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11142526B2 (enExample) |
| EP (1) | EP3675847B1 (enExample) |
| JP (1) | JP7257387B2 (enExample) |
| KR (1) | KR20200046061A (enExample) |
| CN (1) | CN111050765B (enExample) |
| AU (1) | AU2018323459A1 (enExample) |
| BR (1) | BR112020004101A2 (enExample) |
| CA (1) | CA3072923A1 (enExample) |
| CL (1) | CL2020000462A1 (enExample) |
| CO (1) | CO2020001724A2 (enExample) |
| CR (1) | CR20200089A (enExample) |
| DO (1) | DOP2020000039A (enExample) |
| EA (1) | EA202090312A1 (enExample) |
| EC (1) | ECSP20013337A (enExample) |
| ES (1) | ES2952332T3 (enExample) |
| GE (2) | GEP20217327B (enExample) |
| IL (1) | IL272580B (enExample) |
| JO (1) | JOP20200023A1 (enExample) |
| MA (1) | MA50041A (enExample) |
| MX (1) | MX2020002251A (enExample) |
| NI (1) | NI202000014A (enExample) |
| PE (1) | PE20200664A1 (enExample) |
| PH (1) | PH12020500372A1 (enExample) |
| SG (1) | SG11202001022TA (enExample) |
| UA (1) | UA126685C2 (enExample) |
| WO (1) | WO2019046318A1 (enExample) |
| ZA (1) | ZA202001208B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2800565T1 (sl) | 2012-01-06 | 2020-10-30 | Lundbeck La Jolla Research Center, Inc. | Karbamatne spojine in metode izdelave in uporabe le-teh |
| EP3455226B1 (en) | 2016-05-12 | 2020-12-30 | Lundbeck La Jolla Research Center, Inc. | Spirocycle compounds and methods of making and using same |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| PE20200664A1 (es) | 2017-08-29 | 2020-06-11 | Lundbeck La Jolla Research Center Inc | Compuestos espirociclicos y sus metodos de preparacion y uso |
| BR112020003946A2 (pt) | 2017-08-29 | 2020-09-08 | Lundbeck La Jolla Research Center, Inc. | compostos de espirociclo e métodos para produzir e usar os mesmos |
| KR20220034104A (ko) * | 2019-07-09 | 2022-03-17 | 에프. 호프만-라 로슈 아게 | 신규 헤테로고리 화합물 |
| CN116096723A (zh) * | 2020-08-26 | 2023-05-09 | 豪夫迈·罗氏有限公司 | 用作magl抑制剂的杂环化合物 |
| UY39516A (es) | 2020-11-13 | 2022-05-31 | H Lundbeck As | Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión |
| JP7777891B2 (ja) | 2021-12-29 | 2025-12-01 | サイ セラピューティクス インコーポレイテッド | モノアシルグリセロールリパーゼ（ｍａｇｌ）の阻害 |
| KR20250005229A (ko) | 2022-05-04 | 2025-01-09 | 하. 룬드벡 아크티에셀스카브 | 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태 |
| EP4665718A1 (en) | 2023-02-13 | 2025-12-24 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2440803A1 (en) * | 2001-03-07 | 2002-09-12 | Pfizer Products Inc. | Modulators of chemokine receptor activity |
| US20110172230A1 (en) | 2006-08-23 | 2011-07-14 | Takahiro Ishii | Urea compound or salt thereof |
| WO2009111550A1 (en) | 2008-03-05 | 2009-09-11 | Targacept, Inc. | Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloal kanes |
| FR2941696B1 (fr) | 2009-02-05 | 2011-04-15 | Sanofi Aventis | Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
| US20120083476A1 (en) | 2009-06-05 | 2012-04-05 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| CN102575076B (zh) | 2009-09-29 | 2014-08-20 | 普立万公司 | 具有模拟金属或珠光外观的聚酯制品 |
| CA2778484C (en) | 2009-10-23 | 2018-07-31 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
| US9108937B2 (en) | 2010-03-04 | 2015-08-18 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of mGluR2 |
| FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| EP2444084A1 (en) | 2010-10-21 | 2012-04-25 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Use of PI3K inibitors for the treatment of obesity |
| SI2800565T1 (sl) | 2012-01-06 | 2020-10-30 | Lundbeck La Jolla Research Center, Inc. | Karbamatne spojine in metode izdelave in uporabe le-teh |
| DK2900669T3 (da) | 2012-09-25 | 2019-11-04 | Hoffmann La Roche | Hexahydropyrrolo[3,4-C]pyrrolderivater og relaterede forbindelser som autotaxin (ATX)-inhibitorer og som inhibitorer af lysophosphatidsyre (LPA)-produktion til behandling af f.eks. nyresygdomme |
| JP6647592B2 (ja) | 2013-07-03 | 2020-02-14 | ルンドベック ラ ホーヤ リサーチ センター，インク． | ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用 |
| US10093630B2 (en) * | 2014-05-21 | 2018-10-09 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| EP3271352B1 (en) | 2015-03-18 | 2021-05-12 | H. Lundbeck A/S | Piperazine carbamates and methods of making and using same |
| EA035823B1 (ru) | 2015-07-31 | 2020-08-17 | Пфайзер Инк. | 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl |
| WO2017087858A1 (en) | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| TWI738753B (zh) | 2016-03-31 | 2021-09-11 | 日商武田藥品工業股份有限公司 | 雜環化合物 |
| EP3455226B1 (en) | 2016-05-12 | 2020-12-30 | Lundbeck La Jolla Research Center, Inc. | Spirocycle compounds and methods of making and using same |
| JOP20190050A1 (ar) | 2016-09-23 | 2019-03-20 | Bial Portela & C? S A | مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| AU2017361254B2 (en) | 2016-11-16 | 2021-09-23 | H. Lundbeck A/S. | Pharmaceutical formulations |
| JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190106A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| KR102508739B1 (ko) | 2016-11-16 | 2023-03-09 | 하. 룬드벡 아크티에셀스카브 | Magl 억제제의 결정형 |
| PE20200664A1 (es) | 2017-08-29 | 2020-06-11 | Lundbeck La Jolla Research Center Inc | Compuestos espirociclicos y sus metodos de preparacion y uso |
| BR112020003946A2 (pt) | 2017-08-29 | 2020-09-08 | Lundbeck La Jolla Research Center, Inc. | compostos de espirociclo e métodos para produzir e usar os mesmos |
-
2018
- 2018-08-28 PE PE2020000296A patent/PE20200664A1/es unknown
- 2018-08-28 EP EP18850498.9A patent/EP3675847B1/en active Active
- 2018-08-28 MX MX2020002251A patent/MX2020002251A/es unknown
- 2018-08-28 JP JP2020512586A patent/JP7257387B2/ja active Active
- 2018-08-28 KR KR1020207008312A patent/KR20200046061A/ko not_active Ceased
- 2018-08-28 CR CR20200089A patent/CR20200089A/es unknown
- 2018-08-28 AU AU2018323459A patent/AU2018323459A1/en not_active Abandoned
- 2018-08-28 CA CA3072923A patent/CA3072923A1/en active Pending
- 2018-08-28 EA EA202090312A patent/EA202090312A1/ru unknown
- 2018-08-28 US US16/642,717 patent/US11142526B2/en active Active
- 2018-08-28 IL IL272580A patent/IL272580B/en unknown
- 2018-08-28 GE GEAP201815281A patent/GEP20217327B/en unknown
- 2018-08-28 CN CN201880056725.9A patent/CN111050765B/zh active Active
- 2018-08-28 BR BR112020004101-7A patent/BR112020004101A2/pt not_active IP Right Cessation
- 2018-08-28 WO PCT/US2018/048372 patent/WO2019046318A1/en not_active Ceased
- 2018-08-28 GE GEAP202115281A patent/GEAP202115281A/en unknown
- 2018-08-28 ES ES18850498T patent/ES2952332T3/es active Active
- 2018-08-28 MA MA050041A patent/MA50041A/fr unknown
- 2018-08-28 UA UAA202001526A patent/UA126685C2/uk unknown
- 2018-08-28 JO JOP/2020/0023A patent/JOP20200023A1/ar unknown
- 2018-08-28 SG SG11202001022TA patent/SG11202001022TA/en unknown
-
2020
- 2020-02-14 CO CONC2020/0001724A patent/CO2020001724A2/es unknown
- 2020-02-21 DO DO2020000039A patent/DOP2020000039A/es unknown
- 2020-02-21 EC ECSENADI202013337A patent/ECSP20013337A/es unknown
- 2020-02-24 NI NI202000014A patent/NI202000014A/es unknown
- 2020-02-24 PH PH12020500372A patent/PH12020500372A1/en unknown
- 2020-02-25 CL CL2020000462A patent/CL2020000462A1/es unknown
- 2020-02-26 ZA ZA2020/01208A patent/ZA202001208B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3675848A4 (en) | SPIROCYCLUS COMPOUNDS AND METHOD OF MANUFACTURING AND USING THEREOF | |
| MA50041A (fr) | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci | |
| EP3370715A4 (en) | CHIMERIC COMPOUNDS PROVIDED AGAINST PROTEOLYSIS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
| EP3455226A4 (en) | SPIROCYCLIC COMPOUNDS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
| MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
| EP3504213A4 (en) | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHOD FOR USE THEREOF | |
| EP3429635A4 (en) | ANTI-CRISPR COMPOUNDS AND METHOD OF USE | |
| EP3504251A4 (en) | NETWORK POLYMERS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
| EP3645742A4 (en) | Anti-ror1 antibodies and methods of making and using thereof | |
| MA43365A (fr) | Anticorps anti-dr5 et procédés d'utilisation de ceux-ci | |
| EP3778607C0 (en) | BENZOXAZEPINE-OXAZOLIDINONE COMPOUNDS AND METHOD OF USE | |
| MA49752A (fr) | Procédés de préparation de composés de pyrrolidine | |
| MA52492A (fr) | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés | |
| MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
| EP3271352A4 (en) | PIPERAZINE CARBAMATES AND PROCESS FOR THE PREPARATION AND USE THEREOF | |
| EP3504196A4 (en) | METHOD FOR PRODUCING OLAPARIB | |
| MA48942A (fr) | Composés thérapeutiques, compositions et procédés d'utilisation associés | |
| EP3525764A4 (en) | ORAL COMPOSITION OF EXTRACTED CANNABINOIDS AND METHOD FOR USE THEREOF | |
| MA44611A (fr) | Compositions de composés hydrophobes cristallisés et leurs procédés de préparation et d'utilisation | |
| MA49560A (fr) | Composés cétoniques bicycliques et leurs procédés d'utilisation | |
| EP3429754A4 (en) | SAMPLE PREPARATION CARTRIDGES AND METHOD OF USE THEREOF | |
| MA46546A (fr) | Composés thérapeutiques et leurs procédés d'utilisation | |
| EP3468555A4 (en) | ANTIMICROBIAL CONNECTIONS AND METHOD FOR USE THEREOF | |
| EP3662007A4 (en) | SILICA-BASED MATTING AGENTS AND PROCESS FOR THEIR PRODUCTION AND USE | |
| EP3349755A4 (en) | NICOTINE FORMULATIONS AND PROCESS FOR THE PREPARATION AND USE THEREOF |